Share this page

SOHO Society News

SOHO Annual Meeting

Registration is still open for SOHO 2023 On-Demand Content! The eleventh annual meeting of the society, SOHO 2023, was held as a hybrid event (in-person and virtual) from September 6-9, 2023 at the George R. Brown Convention Center in Houston, Texas. Advances in leukemia, lymphoma, myeloma, myeloproliferative neoplasms, myelodysplastic syndromes and related malignancies were highlighted during the official educational program. For more information and to register to view On-Demand content, visit soho.click/2023.

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. The primary purpose of the SOHO meetings are to exchange the latest information in the hematologic oncology field. SOHO is the only global society that focuses solely on blood tumors. Importantly, SOHO meetings include outstanding leaders, innovators and budding young investigators that interact to stimulate progress in this important field.

The 2023 meeting promises to be a dynamic and informative event. SOHO is the premier meeting that focuses specifically on new advances and practical clinical applications in the field of hematologic malignancies. The speakers are a multidisciplinary group of internationally recognized experts that represent the spectrum of these diseases.

This year, more than 2,500 physicians, nurses and related healthcare specialists to participated in the 3.5-day meeting in several unique educational formats including General Sessions, Meet-the-Professor Sessions, Plenary Lectures, Expert Sessions, Oral Abstract Presentations and other interactive and informal exchanges. Topics covered the latest advances in the pathophysiology and therapy of: leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, related malignancies and exciting developments in cellular therapy.

SOHO 2023 On-Demand Abstracts & Poster Winners

Latest Clinical News

Do High Molecular Risk Mutations Increase Leukemia Risk in Myelofibrosis

The multicenter trial studied genetic mutations across three cohorts.

Dr. Nowakowski Gives an Inside Look at the FDA ODAC 'Yes' Vote to Polivy

Grzegorz Nowakowski, MD, recounts his experience serving on the FDA ODAC while reviewing the POLARIX data.

TP-3654 Monotherapy Well-tolerated in Relapsed or Refractory Myelofibrosis

Led by Dr. Lindsay Rein, the goal of the phase I/II trial was to evaluate the safety and efficacy of TP-3654.

Cilta-cel Improved Outcomes in Pretreated Multiple Myeloma Compared with Standard Care

Cilta-cel improved survival outcomes compared with standard care in patients with lenalidomide-refractory multiple myeloma.

First Data on Nemtabrutinib in Relapsed or Refractory Hematologic Malignancies

Nemtabrutinib induced a response in 75% of patients with CLL, and investigators established a phase II dose of 65 mg daily.

Patients with CLL Lack Known Resistance Mechanisms After Disease Progression

Patients with CLL who progressed after ibrutinib and venetoclax did not show mutations linked with treatment resistance.

Molecular Perturbations in Bone Marrow Cells Could Promote MDS

The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.

Lower Dose CPX-351 Is Safe in Patients with HR-MDS

The study determined the maximum tolerated dose of CPX-351, but further studies are needed to evaluate its activity.

Outpatient MCL Treatment Regimen Induces Responses in Mutated MCL

BOVen induced high rates of response and MRD-negativity among patients with untreated MCL with TP53 mutations.

Guillermo Garcia-Manero, MD | SOHO President 2024

The Board of Directors and the Steering committee of the Society of Hematologic Oncology are pleased to announce that Dr. Guillermo Garcia-Manero (GGM) assumed the position of SOHO President on September 10, 2023. He will oversee the society during the 2023-2024 term and will Chair the SOHO 2024 annual meeting scheduled for September 4-7, 2024.

GGM has served on the SOHO Steering, Education and Scientific committees since the inception of the society in 2012. His efforts have focused on improving the outcomes and quality of life of patients with leukemia and, in particular, myelodysplastic syndromes. His work centers around the understanding of the pathophysiology of these disorders in order to develop new therapeutic interventions. He currently leads the largest MDS program in the world and directs the MDS/AML Moon Shot® program at UT MD Anderson Cancer Center (MDACC). This work has resulted in over 500 publications in the areas of biology, therapy and prognostication of these disorders, and development of multiple therapeutic clinical trials.

GGM is the Dr. Kenneth B. McCredie Chair in Clinical Leukemia Research in the Department of Leukemia at MDACC. He also serves as the Chief of the Section of Myelodysplastic Syndromes and Vice Chairman of the Department of Leukemia. In addition, GGM serves as the Program Director of the Leukemia Fellowship Program at MDACC.

GGM was born in Spain and received his medical degree and training at the University of Zaragoza in Spain and at the Royal Free Hospital in London, UK. He completed his internship and residency in Internal Medicine at Thomas Jefferson University Hospital in Philadelphia, PA and his fellowship in Hematology and Medical Oncology at the Cardeza Foundation for Hematology Research, Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital, where he served as Chief Fellow. In 1999, he became Assistant Professor in the Department of Leukemia at MDACC where he continues to improve outcomes for patients diagnosed with MDS and leukemia.

Please join us in congratulating Dr. Garcia-Manero!